The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.50
Bid: 19.00
Ask: 20.00
Change: 0.25 (1.30%)
Spread: 1.00 (5.263%)
Open: 19.25
High: 19.50
Low: 19.00
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

Thu, 04th Jan 2024 08:58

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

The FTSE 100 index opened up 28.37 points, or 0.4%, at 7,710.70. The FTSE 250 was up 62.33 points, 0.3%, at 19,388.73, and the AIM All-Share was 0.61 of a point, 0.1%, at 754.76.

Retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

The Cboe UK 100 was up 0.3% at 769.45, the Cboe UK 250 was up 0.4% at 16,841.68, and the Cboe Small Companies was up 0.1% at 14,879.58.

In European equities, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was up 0.3%.

Sterling was quoted at USD1.2687 early Thursday, higher than USD1.2646 at the London equities close on Wednesday. The euro traded at USD1.0938, higher than USD1.0915. Against the yen, the dollar was quoted at JPY143.61, higher than JPY143.50.

In the FTSE 100, Next rose 4.1%. The retailer said full price sales during November and December were better than it anticipated.

In a trading update covering the nine weeks to December 30, Next said full price sales were up 5.7% from a year earlier, which was GBP39 million than its previous guidance of a 2.0% rise for the period.

Next upped its full-year pretax profit guidance by GBP20 million, or 4.0% to GBP905 million compared to last year, saying GBP17 million of the lift comes from the sales beat to date and GBP3 million from an upgraded forecast for full price sales in January.

"Next's Christmas trading update gave investors plenty to be jolly about," said Hargreaves Lansdown analyst Aarin Chiekrie.

"Successfully keeping full-priced sales front and centre to avoid discounts is one of the reasons Next can boast some of the best margins in the sector. But it's a tricky strategy to nail, especially alongside expanding its online presence and introducing third-party brands to its offering."

JD Sports plunged 20%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

"Our key markets have seen increased promotional activity during the peak trading season, driven by a more cautious consumer, but we continue to grow market share," said JD Sports Chief Executive Officer Regis Schultz.

"We are confident in our strategy and we continue to invest in our supply chain, systems and stores, supported by our strong cash generation and healthy balance sheet."

Oil majors BP and Shell rose 1.4% and 0.9% respectively, tracking improved oil performance. Brent oil was trading at USD78.92 a barrel early Thursday, higher than USD78.13 on Wednesday.

In the FTSE 250, Tritax EuroBox gained 2.0%.

The investor in Continental European logistics real estate said it agreed a new five-year lease with an unnamed Scandinavian photovoltaic company to let its 5,007 square metre unit at its 13,611 square metre two-unit development near Stockholm, Sweden.

The lease begins in March with a 100% consumer price inflation indexation. This will be reviewed annually and includes a further five-year extension option.

Tritax Eurobox said the rent has been agreed at 3% above the estimated rental value as of September and 20% above the underwrite level.

Among London's small-caps, Topps Tiles lost 5.6%.

The retailer said sales in the 13 weeks ended December 30 were down 4.0% from a year earlier, with like-for-like sales down 7.1%.

It explained that trading in the first quarter reflected the ongoing challenges to discretionary consumer spending, particularly those impacting on businesses serving the repair, maintenance and improvement sector.

Topps Tiles expects its full-year profits to be weighted towards the second half, based on a number of factors including the timing of the holiday pay accrual, higher energy usage in the first half and general trading in the first half.

In the US on Wednesday, Wall Street ended lower, with the Dow Jones Industrial Average and the S&P 500 both down 0.8%, while the Nasdaq Composite was down 1.2%.

Federal Reserve officials late Wednesday concluded that interest rate cuts are likely in 2024, although they deemed it would be appropriate to maintain a restrictive stance "for some time," according to minutes of December's meeting.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the minutes stated.

The minutes indicated increased optimism among participants about the path of inflation, noting "clear progress". The committee expressed a willingness to cut the benchmark lending rate in 2024 should that trend continue, though the timing of such a move remained uncertain.

Asian markets largely tracked US stocks into the red, the Nikkei 225 index in Tokyo closed down 0.5%. In China, the Shanghai Composite closed down 0.4%, while the Hang Seng index in Hong Kong was marginally down. The S&P/ASX 200 in Sydney closed down 0.4%.

China's services sector expanded at a faster pace at the end of 2023, according to the latest survey data. The Caixin services purchasing managers' index rose to 52.9 points from 51.5 in November, climbing further above the 50-point no-change mark.

Japanese manufacturing continued to contract in December. The au Jibun Bank manufacturing PMI fell to 47.9 from 48.3 in November, indicating a worsening downturn.

Gold was quoted at USD2,046.61 an ounce early Thursday, higher than USD2,038.89 on Wednesday.

On AIM, Angle soared 38%, after it unveiled "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated".

The medical diagnostics firm said the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions."

Still to come on Thursday's economic calendar, the services PMI for the UK will be released at 0930 GMT. Survey data will also be released for the EU and Germany shortly, followed by the US at 1445 GMT. Consumer price inflation data for Germany is released at 1300 GMT.

Two US jobs data releases also come out in the afternoon: the ADP jobs report at 1315 GMT and initial jobless claims at 1330 GMT.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more
25 Feb 2019 10:51

Angle client demonstrates new use for 'Parsortix' system

(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.